Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000963 Huadong Medicine Co.,Ltd.

Closed 02-27 15:00:00

35.94

+0.21

+0.59%

High35.98	Low35.59	Vol5.72M
Open35.68	D1 Closing35.73	Amplitude1.09%
Mkt Cap63.04B	Tradable Cap63.00B	Total Shares1.75B
T/O205.00M	T/O Rate0.33%	Tradable Shares1.75B
P/B2.6	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":35.94,"timestamp":1772175786000,"preClose":35.73,"halted":0,"volume":5719768,"delay":0,"changeRate":0.0059,"floatShares":1753000000,"shares":1754000000,"eps":2.1082,"marketStatus":"Closed","change":0.21,"latestTime":"02-27 15:00:00","open":35.68,"high":35.98,"low":35.59,"amount":205000000,"amplitude":0.0109,"askPrice":35.94,"askSize":132,"bidPrice":35.93,"bidSize":40,"shortable":0,"etf":0,"ttmEps":2.1082,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":35.73,"symbolType":"stock","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":39.3,"lowLimit":32.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754021048,"isCdr":false,"pbRate":2.6,"roa":"--","peRate":17.047718,"roe":"11.39%","epsLYR":2.0046,"committee":-0.549264,"marketValue":63040000000,"turnoverRate":0.0033,"status":0,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-03-02.","floatMarketCap":63016000000},"requestUrl":"/m/hq/s/000963/tweets","defaultTab":"tweets","newsList":[{"id":"1104849308","title":"Huadong Medicine Appeals to Supreme Court After Losing Initial Patent Lawsuit Against Jolly Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1104849308","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104849308?lang=en_us&edition=fundamental","pubTime":"2026-02-27 10:14","pubTimestamp":1772158459,"startTime":"0","endTime":"0","summary":"Following an unsuccessful initial ruling, Huadong Medicine Co.,Ltd. has proceeded with an appeal. On the evening of February 26, Zhejiang Jolly Pharmaceutical Co.,Ltd. announced that due to a patent...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0209","BK0042","BK0175","BK0132","BK0196","LU1969619763.USD","BK0187","BK0183","BK0188","BK0077","000963","LU2328871848.SGD","BK0239","300181"],"gpt_icon":0},{"id":"2609344880","title":"Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2609344880","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609344880?lang=en_us&edition=fundamental","pubTime":"2026-02-05 12:15","pubTimestamp":1770264933,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) unit, Zhejiang Doer Biologics, obtained approval from China's National Medical Products Administration for the clinical trial of DR10624 injection, according to a Shenz","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0209","BK0132","BK0183","LU2328871848.SGD","BK0188","LU1969619763.USD","BK0196","BK0187","000963","BK0175"],"gpt_icon":0},{"id":"1179334322","title":"Huadong Medicine Subsidiary's DR10624 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1179334322","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179334322?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:56","pubTimestamp":1770198974,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its subsidiary, Zhejiang Daoer Biotechnology Co., Ltd., has obtained a \"Drug Clinical Trial Approval Notice\" issued by the National Medical...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0187","BK0132","BK0209","BK0175","BK0188","BK0196","LU2328871848.SGD","000963","LU1969619763.USD"],"gpt_icon":0},{"id":"2608401336","title":"China's Drug Regulator Accepts Marketing Authorization Application of Huadong Medicine's Unit for Roflumilast Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2608401336","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608401336?lang=en_us&edition=fundamental","pubTime":"2026-02-04 11:56","pubTimestamp":1770177378,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the marketing authorization application from Huadong Medicine's  unit, Hangzhou Sino-American Huadong Pharmaceutical, for roflumilast cream, according to a Wednesday disclosure on the Shenzhen bourse.The overseas-manufactured drug, also named Zoryve, was developed for the topical treatment of mild to moderate atopic dermatitis in patients aged 2 to 5 years.Hangzhou Sino-American received exclusive rights from Arcutis Biotherapeutics to distribute the drug in China and Southeast Asia.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0132","BK0183","BK0209","LU1969619763.USD","BK0175","BK0196","000963","LU2328871848.SGD","BK0187"],"gpt_icon":0},{"id":"1120635069","title":"Huadong Medicine (000963.SZ): Roflumilast Cream Marketing Authorization Application Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1120635069","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120635069?lang=en_us&edition=fundamental","pubTime":"2026-02-03 19:16","pubTimestamp":1770117382,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Zhongmei Huadong), has received a \"Notice of Acceptance\" issued...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0175","BK0132","BK0187","BK0196","BK0209","000963","BK0183","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"1117243250","title":"Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market","url":"https://stock-news.laohu8.com/highlight/detail?id=1117243250","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117243250?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:41","pubTimestamp":1769514072,"startTime":"0","endTime":"0","summary":"On January 27, Huadong Medicine Co.,Ltd. responded to investor inquiries on an interactive platform, stating that HDM1002, as a differentiated oral GLP-1 targeted drug, is specifically positioned to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","GLP","BK0187","BK0132","000963","BK4144","LU1969619763.USD","LU2328871848.SGD","BK4590","BK0209","BK0188","BK0175","BK0183"],"gpt_icon":0},{"id":"2603962406","title":"Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603962406","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603962406?lang=en_us&edition=fundamental","pubTime":"2026-01-15 10:55","pubTimestamp":1768445746,"startTime":"0","endTime":"0","summary":"Huadong Medicine (SHE:000963) subsidiary Dual Bio received the approval of the U.S. Food and Drug Administration to begin clinical trials for DR10624 injection.DR10624 is indicated for metabolic dysfunction-associated steatotic liver disease, according to a Thursday filing with the Shenzhen bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0187","BK0188","LU1969619763.USD","BK0196","LU2328871848.SGD","BK0132","BK0209","BK0183","000963"],"gpt_icon":0},{"id":"2602059573","title":"Huadong Medicine's Hypertriglyceridemia Drug Gains Breakthrough Status in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2602059573","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602059573?lang=en_us&edition=fundamental","pubTime":"2026-01-12 14:26","pubTimestamp":1768199163,"startTime":"0","endTime":"0","summary":"Huadong Medicine (SHE:000963) subsidiary Duality Biotech's novel drug, DR10624 injection, was included in China's breakthrough therapy designation list.DR10624 is indicated for severe hypertriglycerid","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK0187","BK0183","000963","BK0196","BK0209","BK0132","LU2328871848.SGD","BK0175","BK0188"],"gpt_icon":0},{"id":"1144466352","title":"Key Market Catalysts for January 12, 2026: Seven Major Positive Developments to Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=1144466352","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144466352?lang=en_us&edition=fundamental","pubTime":"2026-01-11 22:11","pubTimestamp":1768140673,"startTime":"0","endTime":"0","summary":"On January 11, several listed companies announced positive developments. Defu Technology (301511.SZ) disclosed that it recently signed a Letter of Intent for Acquisition with Anhui Huiru Technology...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0256","BK0183","002969","BK0196","000963","301511","BK0132","LU1969619763.USD","LU2328871848.SGD","BK0187","BK0188","002746","BK0175","BK0194","BK0209","BK0238","BK0214","SINA"],"gpt_icon":0},{"id":"2591961930","title":"China Court Dismisses Huadong Medicine Unit's Copyright Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2591961930","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591961930?lang=en_us&edition=fundamental","pubTime":"2025-12-15 16:25","pubTimestamp":1765787158,"startTime":"0","endTime":"0","summary":"A court in Zhejiang, China, dismissed the case filed by Huadong Medicine  subsidiary Hangzhou Sino-American Huadong Pharmaceutical against three defendants for alleged patent infringement, according to a Monday filing with the Shenzhen bourse.Huadong claimed that one of the defendants, Qinghai Zhufeng Cordyceps Raw Material, copied the listed company's raw material for its Bailin capsules and submitted fake documents, the filing said.The company will file an appeal with China's Supreme People's Court, it said.Shares fell 3% during the close of trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0175","BK0132","BK0187","BK0196","BK0209","000963","BK0183","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2589863953","title":"Huadong Medicine's Two Drugs Placed in China's Insurance Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589863953","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589863953?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:24","pubTimestamp":1765167864,"startTime":"0","endTime":"0","summary":"Two of Huadong Medicine's  drugs were included in China's National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List, according to a Shenzhen bourse filing on Monday.The drugs are senaparib capsules and lina-raserate dimethyl ester capsules.The new list will be effective on Jan. 1, 2026, the Chinese drugmaker said.Meanwhile, the company's zevokio lensa injection was included in the commercial health insurance innovative drug list, while the ustekinumab injection was moved to routine catalog management, with changes to its reimbursement scope.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0183","BK0187","LU1969619763.USD","BK0188","BK0132","000963","BK0209","BK0196","BK0175"],"gpt_icon":0},{"id":"2585505460","title":"Heidelberg Pharma Appoints Dr. Dongzhou Jeffery Liu as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2585505460","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585505460?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:07","pubTimestamp":1763993230,"startTime":"0","endTime":"0","summary":"Heidelberg Pharma AG has announced changes to its management team. Dr. Dongzhou Jeffery Liu has been appointed as a member of the Management Board and Chief Executive Officer, effective December 24, 2025. Dr. Liu previously served as a member of the Supervisory Board and has held leadership roles at Huadong Medicine and several pharmaceutical companies in the United States. Prof. Dr. Andreas Pahl is no longer a member or spokesperson of the Management Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL79qlVS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","000963","BK0209","BK0183","BK0196","BK0175","BK0132","LU2328871848.SGD","BK0188","LU1969619763.USD"],"gpt_icon":0},{"id":"2585452794","title":"Huadong Medicine to Buy Back Restricted Shares for 6.4 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452794","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585452794?lang=en_us&edition=fundamental","pubTime":"2025-11-24 16:57","pubTimestamp":1763974632,"startTime":"0","endTime":"0","summary":"Huadong Medicine  agreed to repurchase and cancel restricted shares for 6.4 million yuan, according to a Shenzhen bourse filing on Saturday.The Chinese drugmaker's shares rose 2% at the close of Monday's trade.The company will buy back 284,200 shares for 22.85 yuan per share.The restricted shares will be bought back after most of the shareholders have resigned from the company.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0132","BK0187","LU2328871848.SGD","BK0188","BK0183","000963","BK0196","LU1969619763.USD","BK0209","BK0175"],"gpt_icon":0},{"id":"2584651600","title":"Huadong Medicine's Unit Gets Nod for Supplementary Application for Imported Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2584651600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584651600?lang=en_us&edition=fundamental","pubTime":"2025-11-18 12:16","pubTimestamp":1763439417,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Hangzhou Zhongmei Huadong Pharmaceutical, received the approval from China's National Medical Products Administration for the supplemental application of imported drug, mirvetuximab soravtansine injection, according to a Shenzhen bourse filing on Tuesday.The drug, which has the trade name Elahere, is used to treat patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Its previously conditionally approved indication is now converted to regular approval.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0196","000963","BK0132","LU1969619763.USD","LU2328871848.SGD","BK0187","BK0188","BK0175","BK0209"],"gpt_icon":0},{"id":"2583527807","title":"Chinese doctors call for insurance coverage for weight-loss drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2583527807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583527807?lang=en_us&edition=fundamental","pubTime":"2025-11-14 15:14","pubTimestamp":1763104497,"startTime":"0","endTime":"0","summary":"Chinese doctors call for insurance coverage for weight-loss drugsObesity China's sixth leading risk factor in disability, deathNumber of overweight, obese to increase to 65% by 2030Weight-loss drugs too expensive, doctors sayGenerics could bring price pressure, Goldman Sachs analysts sayBy Andrew Silver","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL6N3WN0C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0315179316.USD","BK1515","LU1152091754.HKD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1152091168.USD","02566","LU2097828805.USD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1328277881.USD","BK0132","LU0501845795.SGD","BK0209","LU0072913022.USD","LU0067412154.USD","01093","IE0008368742.USD","LU1813983027.USD","BK0187","IE00B543WZ88.USD","LU2242644610.SGD","IE00BZ08YT58.USD","LU1969619763.USD","IE0008369823.USD","LU1226287792.SGD","HK0000165453.HKD","BK1521","IE00B031HY20.USD","LU2097828557.USD","LU1951186391.HKD","IE00BZ08YS42.EUR","BK1583","LU2039709279.SGD","BK1191","LU2097828474.EUR","000963","LU1226287875.USD","BK0175","01801","SG9999004220.SGD","BK1589","LU1993786604.SGD","NHC","LU1960683339.HKD","LU1226288170.HKD","LU2097828714.EUR","LU2097828631.EUR","LU1226287529.USD"],"gpt_icon":0},{"id":"2582469523","title":"Huadong Medicine Unit Secures Acceptance of New Drug Application for Topical Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2582469523","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582469523?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:13","pubTimestamp":1762924425,"startTime":"0","endTime":"0","summary":"Huadong Medicine  subsidiary Zhongmei Huadong has received acceptance from China's drug administrator for the new drug application for roflumilast cream.The drug is intended for the topical treatment of mild to moderate atopic dermatitis, according to a Wednesday filing with the Shenzhen bourse.Shares of the drugmaker rose 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0175","LU2328871848.SGD","LU1969619763.USD","BK0209","BK0183","BK0132","000963","BK0187","BK0188"],"gpt_icon":0},{"id":"1161188721","title":"Huadong Medicine (000963.SZ) Receives NMPA Acceptance for Roflumilast Cream (ZORYVE®) 0.15% Marketing Authorization Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1161188721","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161188721?lang=en_us&edition=fundamental","pubTime":"2025-11-11 17:44","pubTimestamp":1762854261,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co., Ltd. (000963.SZ) announced on November 10, 2025, that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received the \"Acceptance Notice\"...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0132","BK0183","BK0209","LU1969619763.USD","BK0175","BK0196","000963","LU2328871848.SGD","BK0187"],"gpt_icon":0},{"id":"2580525210","title":"Chinese Drug Administration Accepts Marketing Application of Huadong Medicine's Unit for Roflumilast Cream; Shares Up 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580525210","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580525210?lang=en_us&edition=fundamental","pubTime":"2025-11-03 12:16","pubTimestamp":1762143364,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted the marketing application of Huadong Medicine's  unit, Hangzhou Sino-American East China Pharmaceutical, for Roflumilast Cream, according to a Saturday filing on the Shenzhen bourse.The shares rose less than 1% during Monday's midday trade.The overseas-manufactured drug, which has the trade name Zoryve, treats plaque psoriasis in patients aged 6 years old and above.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0175","BK0132","BK0187","BK0196","BK0209","000963","BK0183","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2578998392","title":"Huadong Medicine's Q3 Profit Rises 8%, Revenue Climbs Nearly 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578998392","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578998392?lang=en_us&edition=fundamental","pubTime":"2025-10-28 13:08","pubTimestamp":1761628136,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  net profit attributable to shareholders in the third quarter rose 7.7% year on year to 933.1 million yuan, according to a Shenzhen bourse filing on Tuesday.Earnings per share increased 7.4% from a year earlier to 0.532 yuan.Operating revenue climbed 4.5% year on year to almost 11 billion yuan, the Chinese drugmaker said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0209","BK0183","BK0132","BK0175","BK0188","BK0196","000963","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"1182081460","title":"Huadong Medicine Co.,Ltd. (000963.SZ) Reports Q3 Results: Net Profit Up 7.24% YoY to RMB 2.748 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1182081460","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182081460?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:50","pubTimestamp":1761587428,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) released its third-quarter report for 2025, showing revenue of RMB 32.664 billion for the first nine months, a year-on-year increase of 3.77%. Net profit...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK0188","BK0183","BK0132","LU1969619763.USD","000963","BK0196","BK0209","BK0175","BK0187"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","stockEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":-0.0086},{"period":"3month","weight":-0.1443},{"period":"6month","weight":-0.182},{"period":"1year","weight":0.0317},{"period":"ytd","weight":-0.089}],"companyName":"华东医药股份有限公司","boardCode":"AI0052","perCapita":"25487股","boardName":"零售业","registeredCapital":"175402万元","compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"survey":"　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。","serverTime":1772230443606,"listedPrice":5.76,"stockholders":"68793人(较上一季度减少1.50%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction